Prediction of total propofol clearance based on enzyme activities in microsomes from human kidney and liver

European Journal of Clinical Pharmacology

Volumn 62, Issue 7, 2006, Pages 527-533

  Al Jahdari, Wael S ^a   Yamamoto, Koujirou ^a   Hiraoka, Haruhiko ^a   Nakamura, Katsunori ^a   Goto, Fumio ^a   Horiuchi, Ryuya ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Intrinsic clearance; Propofol glucuronidation; Propofol oxidation; Scale up

Indexed keywords

BILIRUBIN; CREATININE; CYTOCHROME P450; DRUG METABOLITE; PROPOFOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ADULT; AFRICAN AMERICAN; AGED; ANESTHESIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; CAUCASIAN; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY BLOOD FLOW; KIDNEY CLEARANCE; KIDNEY MICROSOME; KIDNEY TUMOR; LIVER BLOOD FLOW; LIVER CLEARANCE; LIVER MICROSOME; MALE; MATHEMATICAL MODEL; MICHAELIS CONSTANT; MICHAELIS MENTEN KINETICS; NEPHRECTOMY; PRIORITY JOURNAL; SEDATION;

AGED; AGED, 80 AND OVER; ANESTHETICS, INTRAVENOUS; FEMALE; GLUCURONIDES; HUMANS; KIDNEY; KINETICS; MALE; METABOLIC CLEARANCE RATE; MICROSOMES; MICROSOMES, LIVER; MIDDLE AGED; PROPOFOL;

EID: 33745727113     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0130-2     Document Type: Article

References (30)

1. Hiraoka H, Yamamoto K, Okano N, Morita T, Goto F, Horiuchi R (2004) Changes in drug plasma concentrations of extensively bound and highly extracted drug, propofol, in response to altered plasma binding. Clin Pharmacol Ther 75:324-330
2. Takizawa D, Hiraoka H, Nakamura K, Yamamoto K, Horiuchi R (2004) Propofol concentrations during the anhepatic phase of living-related donor liver transplantation. Clin Pharmacol Ther 76:648-649
3. Takizawa D, Hiraoka H, Goto F, Yamamoto K, Horiuchi R (2005) Human kidneys play an important role in the elimination of propofol. Anesthesiology 102:327-330
4. Hiraoka H, Yamamoto K, Miyoshi S, Morita T, Nakamura K, Kadoi Y, Kunimoto F, Horiuchi R (2005) Kidneys contribute to the extrahepatic clearance of propofol in humans but not lungs or brain. Br J Clin Pharmacol 60:176-182
5. Favetta P, Degoute CS, Perdrix JP, Dufresne C, Boulieu R, Guitton J (2002) Propofol metabolites in man following propofol induction and maintenance. Br J Anaesth 88:653-658
6. Court MH, Duan SX, Hesse LM, Venkatakrishnan K, Greenblatt DJ (2001) Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology 94:110-119
7. Oda Y, Hamaoka N, Hiroi T, Imaoka S, Hase I, Tanaka K, Funae Y, Ishizaki T, Asada A (2001) Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. Br J Clin Pharmacol 51:281-285
8. Ethell BT, Beaumont K, Rance DJ, Burchell B (2001) Use of cloned and expressed human UDP-glucuronosyltransferases for the assessment of human drug conjugation and identification of potential drug interactions. Drug Metab Dispos 29:48-53
9. Cheng Z, Radominska-Pandya A, Tephly TR (1999) Studies on the substrate specificity of human intestinal UDP-glucuronosyltransferases 1A8 and 1A10. Drug Metab Dispos 27:1165-1170
10. Raoof AA, van Obbergh LJ, de Ville de Goyet J, Verbeeck RK (1996) Extrahepatic glucuronidation of propofol in man: possible contribution of gut wall and kidney. Eur J Clin Pharmacol 50:91-96
11. McGurk KA, Brierley CH, Burchell B (1998) Drug glucuronidation by human renal UDP-glucuronosyltransferases. Biochem Pharmacol 55:1005-1012
12. Kitagawa H, Kamataki T (1971) Studies on drug metabolism. XII. Activity of liver microsomal drug-metabolizing enzymes in human liver. Chem Pharm Bull (Tokyo) 19:827-830
13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275
14. Fisher MB, Campanale K, Ackermann BL, VandenBranden M, Wrighton SA (2000) In vitro glucuronidation using Human Liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 28:560-566
15. Vree TB, Baars AM, de Grood PM (1987) High performance liquid chromatographic determination and preliminary pharmacokinetics of propofol and its metabolites in human plasma and urine. J Chromatog 417:458-464
16. Carlile DJ, Stevens AJ, Ashforth EI, Waghela D, Houston JB (1998) In vivo clearance of ethoxycoumarin and its prediction from In vitro systems. Use Of drug depletion and metabolite formation methods in hepatic microsomes and isolated hepatocytes. Drug Metab Dispos 26:216-221
17. Omura T, Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378
18. Strobel H, Dignam D (1978) Purification and properties of NADPH-cytochrome P450 reductase. In: Fleischer S, Packer L (eds) Methods in enzymology, vol. 52. Academic Press, New York, pp 89-96
19. Wilson ZE, Rostami-Hodjegan A, Burn JL, Tooley A, Boyle J, Ellis SW, Tucker GT (2003) Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol 56:433-40. Erratum in: Br J Clin Pharmacol 2004 Dec;58:680
20. Gillette J (1963) Drug metabolism by enzyme mechanism. Prog Drug Res 6:55-57
21. Bickel MH, Steele JW (1974) Binding of basic and acidic drugs to rat tissue subcellular fractions. Chem-Biol Interact 8:151-162
22. Di Francesco C, Bickel MH (1977) Membrane lipids as intracellular binders of chlorpromazine and related drugs. Chem-Biol Interact 16:335-346
23. Obach RS (1997) Non specific binding to microsomes: Impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine and propranolol. Drug Metab Dispos 25:1359-1369
24. Soars MG, Burchell B, Riley RJ (2002) In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol ExpTher 30:382-390
25. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171
26. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479
27. Veroli P, O'Kelly B, Bertrand F, Trouvin JH, Farinotti R, Ecoffey C (1992) Extrahepatic metabolism of propofol in man during the anhepatic phase of orthotopic liver transplantation. Br J Anaesth 68:183-186
28. Aleksa K, Matsell D, Krausz K, Gelboin H, Ito S, Koren G (2005) Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity. Pediatr Nephrol 20:872-885
29. Berg CL, Radominska A, Lester R, Gollan JL (1995) Membrane translocation and regulation of uridine diphosphate-glucuronic acid uptake in rat liver microsomal vesicles. Gastroenterology 108:183-192
30. Yokota H, Ando F, Iwano H, Yuasa A (1998) Inhibitory effect of uridine diphosphate on UDP- glucuronosyltransferase. Life Sci 63:1693-1699